Indicators

Latest News about AGNPF

Recent news which mentions AGNPF

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More

April 17, 2024

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design

April 03, 2024

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More

August 14, 2023

DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study

August 08, 2023

DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up

June 05, 2023

How To Finance A Psychedelics Business? Learn From These Four Companies

April 04, 2023

Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment

April 04, 2023

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More

March 07, 2023

Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI

March 03, 2023

Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program

March 01, 2023

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More

February 27, 2023

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More

February 21, 2023

Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program

February 21, 2023

Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose

February 16, 2023

A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing

January 18, 2023

Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One

January 03, 2023

EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans

December 15, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More

November 21, 2022

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon

November 16, 2022

Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University

October 24, 2022

A Foundational Study On Stroke Is Ready. Here Is Why It's Important

September 12, 2022

Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment

September 08, 2022

Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution

August 23, 2022

Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study

July 18, 2022

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation

October 18, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are

October 13, 2021

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics

September 13, 2021

Investors Should Avoid High-Risk Atossa Therapeutics

August 02, 2021

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.